Page 29 - Binding Affinity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness Through advantageous mutations that can occur at the virus’s spike protein, tests have shown that the emergence of several new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can help the virus to infect human host cells more efficiently. Despite various mitigation measures, the coronavirus disease 2019 (COVID-19) pandemic continues, with more than 138.7 million people infected and over 3 million deaths. Research to understand viral pathogenesis, large-scale vaccine administra...

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to wreak its havoc the world over, seemingly remaining one step ahead of scientists. With the rollout of SARS-CoV-2 vaccines, the focus shifted to making vaccines available in the vast quantities required for the global immunization effort. However, the emergence of multiple antibody-resistant mutants has cast doubts on the success of this strategy. Especially concerning are the three variants of concern (VOCs), namely, B.1.1.7 (20...

Mutations from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have created multiple variants. Some variants, such as those found in South Africa and Brazil, have caused concern for their potential to evade the immune response. While vaccination efforts are underway, the world is racing against the viruses’ ability to evolve under selective pressure.

Previously approved drugs starting points for COVID-19 therapeutics Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19). By screening a commercial library of drugs that have already been approved by international regulatory agencies, the team identified more than 50 compounds that demonstrated some efficacy in blocking the initial stage of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19. The compound...

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their results are currently available on the bioRxiv* preprint server. SARS-CoV-2, the causative agent of the ongoing coronavirus disease (COVID-19), uses its spike glycoprotein to interact with angiotensin-converting enzyme 2 (ACE2) in ...